Company intelligence / Profile preview

BioSurface Engineering Technologies, Inc.

College Park, Maryland, United Statesbiospace.com ↗

Ownership: Private
Employees: ~50
Development stage: Preclinical

Overview

The company had two Phase III-ready orthobiologic product candidates (AMPLEX and PREFIX) designed to improve bone repair before being acquired by Ferring Pharmaceuticals in 2015.

Therapeutic areas: GastroenterologyCardiovascularRheumatologyDermatology
Modalities: Synthetic growth factor peptidesdrug delivery technology
Industry: Biotech

Partnerships

EBI, LP (subsidiary of Biomet, Inc.)Biomet, Inc.

Beyond the preview

Go deeper on BioSurface Engineering Technologies, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BioSurface Engineering Technologies, Inc..

Explore the full profile